Biomarin Pharmaceutical Inc (BMRN)

BMRN (NASDAQ:Drugs) EQUITY
$70.08
pos +0.00
+0.00%
Today's Range: 67.07 - 71.25 | BMRN Avg Daily Volume: 1,696,100
Last Update: 02/12/16 - 4:00 PM EST
Volume: 0
YTD Performance: -33.09%
Open: $0.00
Previous Close: $67.26
52 Week Range: $62.12 - $151.75
Oustanding Shares: 161,251,715
Market Cap: 10,845,790,351
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 9
Moderate Buy 1 1 1 1
Hold 4 4 4 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.64 1.64 1.64 1.54
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -33.80
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-33.80 0.00 26.86
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-34.36% -29.05% 27.87%
GROWTH 12 Mo 3 Yr CAGR
Revenue 36.90 0.70 0.19
Net Income 0.00 1.49 0.00
EPS 0.00 0.92 0.00
Earnings for BMRN:
EBITDA -0.10B
Revenue 0.75B
Average Earnings Estimates
Qtr (12/15) Qtr (03/16) FY (12/15) FY (12/16)
Average Estimate $1.00 $-0.96 $-0.46 $-2.07
Number of Analysts 12 7 11 13
High Estimate $1.58 $-0.40 $0.26 $-1.12
Low Estimate $0.81 $-2.94 $-0.65 $-4.40
Prior Year $-0.30 $-0.25 $-0.77 $-0.46
Growth Rate (Year over Year) 434.17% -282.86% 39.91% -346.85%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
BMRN could re-base in the weeks and months ahead as downside looks limited. 
Also, Pfizer-Allergan deal clears another hurdle.
Once again, buyers are going for the gusto.
Drug companies are just too big a target to ignore.
Which means interest rate hikes are being built into prices.
The bulls can show them around the place.
Coal and renewables could both react as political and legal battles ensue.
BioMarin's chart has a well-defined uptrend line and shows great relative strength.

Biotech Stocks Are Booming Real Money Pro($)

I like BioMarin because it has more upside and solid Relative Strength.

Columnist Conversations

I respectfully disagree. Scalia's passing will likely have little impact on the electorate or on a partisan Wa...
All; I've received a few questions about the subject of my column for this weekend about the implications of a...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.